173 related articles for article (PubMed ID: 7527291)
21. [Neonatal screening for cystic fibrosis].
Tellería Orriols JJ; Alonso Ramos MJ; Garrote Adrados JA; Fernández Carvajal I; Blanco Quirós A
An Esp Pediatr; 2002 Jul; 57(1):60-5. PubMed ID: 12139895
[TBL] [Abstract][Full Text] [Related]
22. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
23. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?
Scotet V; Audrézet MP; Roussey M; Rault G; Dirou-Prigent A; Journel H; Moisan-Petit V; Storni V; Férec C
Pediatrics; 2006 Nov; 118(5):e1523-9. PubMed ID: 17015492
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels.
Massie RJ; Wilcken B; Van Asperen P; Dorney S; Gruca M; Wiley V; Gaskin K
J Pediatr; 2000 Aug; 137(2):214-20. PubMed ID: 10931414
[TBL] [Abstract][Full Text] [Related]
25. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
[No Abstract] [Full Text] [Related]
26. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
[TBL] [Abstract][Full Text] [Related]
27. Extended gene analysis can increase specificity of neonatal screening for cystic fibrosis.
Mérelle ME; Scheffer H; De Jong D; Dankert-Roelse JE
Acta Paediatr; 2006 Nov; 95(11):1424-8. PubMed ID: 17062471
[TBL] [Abstract][Full Text] [Related]
28. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
Sommerburg O; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Stopsack M; Gahr M; Hoffmann GF; Mall MA
Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230
[TBL] [Abstract][Full Text] [Related]
29. [Immunoreactive trypsin in the serum of normal children and children with gastrointestinal diseases].
Dockter G; Steyns M; Biro G; Sitzmann FC
Monatsschr Kinderheilkd; 1984 Aug; 132(8):589-93. PubMed ID: 6482880
[TBL] [Abstract][Full Text] [Related]
30. Exocrine pancreatic function in cystic fibrosis.
Guy-Crotte O; Carrère J; Figarella C
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):755-9. PubMed ID: 8864671
[TBL] [Abstract][Full Text] [Related]
31. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
De Boeck K; Weren M; Proesmans M; Kerem E
Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
[TBL] [Abstract][Full Text] [Related]
32. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.
Rock MJ; Mischler EH; Farrell PM; Wei LJ; Bruns WT; Hassemer DJ; Laessig RH
Pediatrics; 1990 Jun; 85(6):1001-7. PubMed ID: 2187173
[TBL] [Abstract][Full Text] [Related]
33. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
[TBL] [Abstract][Full Text] [Related]
34. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
35. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
[TBL] [Abstract][Full Text] [Related]
36. High heterogeneity of CFTR mutations and unexpected low incidence of cystic fibrosis in the Mediterranean France.
des Georges M; Guittard C; Altiéri JP; Templin C; Sarles J; Sarda P; Claustres M
J Cyst Fibros; 2004 Dec; 3(4):265-72. PubMed ID: 15698946
[TBL] [Abstract][Full Text] [Related]
37. Comparison between two newborn screening strategies for cystic fibrosis in Argentina: IRT/IRT versus IRT/PAP.
Teper A; Smithuis F; Rodríguez V; Salvaggio O; Maccallini G; Aranda C; Lubovich S; Zaragoza S; García-Bournissen F
Pediatr Pulmonol; 2021 Jan; 56(1):113-119. PubMed ID: 33095477
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.
van der Ploeg CP; van den Akker-van Marle ME; Vernooij-van Langen AM; Elvers LH; Gille JJ; Verkerk PH; Dankert-Roelse JE;
J Cyst Fibros; 2015 Mar; 14(2):194-202. PubMed ID: 25213034
[TBL] [Abstract][Full Text] [Related]
39. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net.
Sommerburg O; Stahl M; Hämmerling S; Gramer G; Muckenthaler MU; Okun J; Kohlmüller D; Happich M; Kulozik AE; Mall MA; Hoffmann GF
J Cyst Fibros; 2022 May; 21(3):422-433. PubMed ID: 34764021
[TBL] [Abstract][Full Text] [Related]
40. [Mucoviscidosis screening of newborn infants in the Dresden district. Results from 1 June 1996 to 31 March 2000].
Wunderlich P; Stopsack M; Paul KD; Rösen-Wolff A
Dtsch Med Wochenschr; 2000 Nov; 125(45):1356-60. PubMed ID: 11109423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]